Curis competitors

Curis's competitors include Ourotech, Immune Design, Aeglea Biotherapeutics and Heat Biologics
Add company...
Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers.
Ourotech
Ourotech is changing the way cancer drugs are tested for the most innovative treatments.
Immune Design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.
Aeglea Biotherapeutics
Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.
Heat Biologics
Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.
Founding Date
Founding Date
2000
Founding Date
2015
Founding Date
2008
Founding Date
2013
Founding Date
2008
Type
Type
Public
Type
Private
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Lexington, US HQ
Locations
Waterloo, CA HQ
Locations
Seattle, US HQ
South San Francisco, US
Locations
Austin, US HQ
Locations
Durham, US HQ
Employees
Employees
58
Employees
433% increase
Employees
50
Employees
4518% increase
Employees
19
Valuation ($)
Valuation ($)
80.2 m
Valuation ($)
N/A
Valuation ($)
216.6 m
Valuation ($)
227.3 m
Valuation ($)
43.7 m
Facebook likes
Facebook likes
N/A
Facebook likes
504
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
110
Twitter followers
Twitter followers
52
Twitter followers
272
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$9.9m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$7.2m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Net income
Net income
($53.3m) (FY, 2017)
Net income
N/A
Net income
($51.9m) (FY, 2017)
Net income
($27.2m) (FY, 2017)
Net income
($12.4m) (FY, 2017)

Operating

Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Ourotech
HQ
Waterloo, CA
Employees
4↑ 33% increase

Ourotech is changing the way cancer drugs are tested for the most innovative treatments.

View company
Immune Design
HQ
Seattle, US
Employees
50

Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.

View company
Aeglea Biotherapeutics
HQ
Austin, US
Employees
45↑ 18% increase

Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.

View company
Heat Biologics
HQ
Durham, US
Employees
19

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

View company